Últimas noticias sobre Quince Therapeutics (NASDAQ:QNCX) Bolsa

QUINCE THERAPEUTICS INC

Quince Therapeutics

Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.

Quince Therapeutics Inc

Reddit Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) shares are trading higher Monday following reports the company introduced two new AI-powered advertising tools intended to support brands in navigating the platform's <a href="https://www.benzinga.com/markets/tech/25/06/45943729/reddit-is-the-second-most-cited-source-in-google-ai-overviews-but-logged-out-traffic-may-undercut-revenue-gains">complex user discussions</a>.
What To Know: The first tool, "Reddit Insights," allows advertisers to access real-time data about trends and conversations across the platform, which can be used to test or adjust marketing strategies, according to Reuters. 
The second feature, "Conversation Summary Add-ons," enables brands to display select user comments beneath their ads, specifically those considered positive or supportive of the ad's subject matter. Reddit framed this as a way to help advertisers build credibility using authentic community voices.
The report indicates that WPP Media, a major media buying agency, recently downgraded its forecast for global ad revenue growth this year due to shifting U.S. trade policies. That makes AI-based tools more significant for ad platforms trying to convince brands to spend amid a cautious economic climate.
Separately, Reddit's content is showing up more frequently in Google's AI-generated search overviews. Data from <a href="https://www.benzinga.com/markets/tech/25/06/45943729/reddit-is-the-second-most-cited-source-in-google-ai-overviews-but-logged-out-traffic-may-undercut-revenue-gains">Semrush</a> shows Reddit is now the second-most cited source in Google's summaries, just behind Quora. The increase in visibility comes on the heels of Reddit's $60 million content licensing deal with Google in 2024, allowing Google to use Reddit's data for training AI and surfacing results.
Analysts have noted that a large portion of Reddit's recent traffic growth has come from users who don't log into the site, often arriving from a Google search just to find a quick answer and leaving soon after. These visitors don't contribute much to Reddit's ad-based business model, which relies heavily on engaged, logged-in users. Further complicating the situation, Google's AI-generated summaries reduce the need for users to even click through to Reddit, potentially cutting off traffic before it arrives.
Despite Reddit's forecast in May that second-quarter revenue would exceed expectations, CEO Steve Huffman acknowledged that increased integration with Google's AI services might impact site traffic. 
RDDT Price Action: Reddit shares were up 4.66% at $123.70 at the time of publication Monday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45952716/stock-market-today-sp500-rises-iran-israel-nasdaq-near-record-highs">Wall Street Roars Back As Iran Signals De-Escalation: Nasdaq 100 Nears All-Time High </a></li>
</ul>
Image via shutterstock.

News

Social Media

Movers

RDDT

What's Going On With Reddit Stock Today?

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares have been taking a bumper-car spin over the last few weeks, dropping 7% after a very public spat between CEO Elon Musk <a href="https://www.benzinga.com/news/politics/25/06/45800612/trump-says-musk-has-trump-derangement-syndrome-as-battle-over-bill-heats-up-had-a-great-relationship-dont-know-if-we-will-anymore">and President Donald Trump</a>.
After Musk made <a href="https://www.benzinga.com/markets/tech/25/06/45877591/elon-musk-says-he-regrets-war-of-words-with-trump-went-too-far">a political mea culpa</a>, the stock price spiked around 5% last week. But for ETF investors, the question on everyone&#8217;s mind isn&#8217;t an apology; it&#8217;s exposure.
<h2 class="wp-block-heading">The Musk-Trump Drama: Why It Matters For ETFs</h2>
Central to the drama is a proposed threat to Tesla&#8217;s regulatory lifeline: government subsidies and zero-emission vehicle (ZEV) credits. 
When Trump <a href="https://truthsocial.com/@realDonaldTrump/posts/114632206992330264">threatened</a> to strip <a href="https://www.benzinga.com/news/politics/25/06/45942949/white-house-orders-scrutiny-of-spacex-contracts-even-as-trump-musk-relationship-warms-report">federal benefits reaped by Tesla and SpaceX</a>, Musk <a href="https://www.wsj.com/livecoverage/trump-elon-musk-feud/card/musk-tweets-yes-on-post-about-impeaching-trump-DHtPoZq40khLH6A2r15i?gaa_at=eafs&amp;gaa_n=ASWzDAiLs8J-bqzUbH_JJcmWgYzqsqfxXjeiWLkcz0m17EAW_2Ydwq8dTeYma24UBOw%3D&amp;gaa_ts=685051cc&amp;gaa_sig=7yxYAiAq0-pgmvgP84aEUSR0kCGuS8fwkhiK9RUFdTDP2HgCJhKeBHHKV5CJeFSWQ44axE6KA_l1Zfa182qOJA%3D%3D">expressed</a> support for impeaching the president. The back-and-forth rang the alarm bells of the EV investing community, particularly for ETFs with big Tesla holdings.
<a href="https://www.benzinga.com/topic/elon-musk">Musk</a> subsequently retracted his comments, but the damage had already been done. The specter of policy whiplash now hangs over Tesla&#8217;s government-subsidized revenue streams, such as the ZEV credits that have generously buffered its balance sheet.
Also Read: <a href="https://www.benzinga.com/etfs/new-etfs/25/06/45954721/schwabs-new-money-market-etf-sgvt-lets-you-earn-on-idle-cash">Schwab&#8217;s New Money Market ETF SGVT Lets You Earn On Idle Cash</a>
<h2 class="wp-block-heading">The ETF Fallout (And Recovery)</h2>
Tesla&#8217;s whiplash was also reflected in its ETF entourage. Simplify Volt TSLA Revolution ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TESL#NYSE">TESL</a>) and Roundhill TSLA WeeklyPay ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/TSLW#BATS">TSLW</a>) jumped more than 6% and 5%, respectively, last week. Broader consumer-oriented ETFs such as XLY and Nightview Fund NITE (NITE) merely ticked up or fell.
These funds reflect the range of Tesla exposure:
TESL and TSLW provide focused Tesla bets with options overlays to control the risk of the downside, ideal in concept, but still susceptible to Musk-triggered turbulence.
The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>), provides diversified exposure but nevertheless includes Tesla as a leading holding, with more than 17% weightage at present.
NITE, with a 20%+ Tesla exposure, also demonstrates the way smaller (than single-stock funds) allocations can be moved by TSLA&#8217;s mood swings.
<h2 class="wp-block-heading">Robotaxis And AI To The Rescue?</h2>
Joining the narrative, Tesla will launch its robotaxi service &#8220;Cybercab&#8221; on June 22 in Austin, a likely market-moving moment. Analyst Dan Ives at Wedbush thinks this can be a defining moment that can help Tesla reach a $2 trillion valuation in the long term. He thinks AI is now the core growth driver of the company.
&#8220;We estimate the AI and autonomous opportunity is worth at least $1 trillion alone for Tesla and we fully expect under a Trump White House these key initiatives will get fast tracked (despite the Musk beef) as the federal regulatory spiderweb that Musk &amp; Co. have encountered over the past few years around FSD/autonomous clears significantly under Trump given his focus on AI dominance over China,&#8221; said Ives. &#8220;We believe Tesla could reach a $2 trillion market cap by the end of 2026 in a bull case scenario. The $1 trillion of AI valuation will start to get unlocked in the Tesla story and we believe the march to a $2 trillion valuation for TSLA has now begun in our view with FSD and autonomous penetration of Tesla&#8217;s installed base and the acceleration of Cybercab in the US representing the golden goose.&#8221;
Tesla is doubling down on AI, plowing forward with its Dojo supercomputer, Optimus humanoid robots, and Full Self-Driving tech. If AI becomes Tesla&#8217;s central narrative, it can provide a story pivot ETF investors will believe in.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45942936/elon-musks-cybercab-ambitions-just-got-a-boost-as-nhtsa-eases-regulations-for-autonomous-vehicles">Where&#8217;s The Innovation, Elon? &#8216;Worst&#8217; Tesla Upgrade Sparks Backlash</a></li>
</ul>
 Image: Shutterstock

Specialty ETFs

Tech

ETFs

TESL

TSLA

TSLW

Select Sector SPDR-Consumer Discretionary

How Musk's Political Drama With Trump Steers These 3 Tesla ETFs

Evercore ISI Group analyst Mark Mahaney maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Outperform and raises the price target from $650 to $750.

Price Target

Analyst Ratings

SPOT

Evercore ISI Group Maintains Outperform on Spotify Technology, Raises Price Target to $750

Evercore ISI Group analyst David Motemeden maintains FactSet Research Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDS#NYSE">FDS</a>) with a In-Line and lowers the price target from $470 to $448.

Evercore ISI Group Maintains In-Line on FactSet Research Systems, Lowers Price Target to $448

USA 20-Year Bond Auction 4.942% vs 5.104% prior reading.

Econ #s

Economics

USA 20-Year Bond Auction 4.942% vs 5.104% Prior

<h3>Gainers</h3>
<ul>
<li>Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares moved upwards by 35.7% to $9.1 during Monday's regular session. The market value of their outstanding shares is at $569.5 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock moved upwards by 30.04% to $0.03. The market value of their outstanding shares is at $10.7 million. </li>
<li>Immuneering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) stock moved upwards by 18.94% to $2.26. The market value of their outstanding shares is at $81.3 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock increased by 18.01% to $0.14. </li>
<li>Know Labs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KNW#AMEX">KNW</a>) stock increased by 17.68% to $3.86. The market value of their outstanding shares is at $28.7 million. </li>
<li>Geovax Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOVX#NASDAQ">GOVX</a>) shares moved upwards by 17.47% to $1.21. The company's market cap stands at $18.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares decreased by 44.8% to $19.96 during Monday's regular session. The market value of their outstanding shares is at $1.9 billion. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock decreased by 27.34% to $0.37. </li>
<li>NextCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTC#NASDAQ">NXTC</a>) stock fell 26.72% to $0.5. The company's market cap stands at $13.9 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares decreased by 19.98% to $0.33. The market value of their outstanding shares is at $7.8 million. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares declined by 18.89% to $1.16. The market value of their outstanding shares is at $20.3 million. </li>
<li>OKYO Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKYO#NASDAQ">OKYO</a>) stock fell 15.95% to $2.53. The market value of their outstanding shares is at $85.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CYCC

GOVX

HCTI

HSDT

IMNN

IMRX

NCNA

NXTC

OKYO

SAGE

SRPT

12 Health Care Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>OceanPal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OP#NASDAQ">OP</a>) shares rose 36.5% to $2.2 during Monday's regular session. The market value of their outstanding shares is at $16.4 million. </li>
<li>Aeries Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AERT#NASDAQ">AERT</a>) shares rose 32.52% to $1.11. The company's market cap stands at $49.4 million. </li>
<li>Smart Powerr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREG#NASDAQ">CREG</a>) shares rose 32.31% to $0.76. The market value of their outstanding shares is at $19.0 million. </li>
<li>Perma-Pipe Inlt Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPIH#NASDAQ">PPIH</a>) stock moved upwards by 24.35% to $21.55. The company's market cap stands at $172.0 million. The company's, Q1 earnings came out yesterday. </li>
<li>Safe &amp; Green Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) shares rose 21.77% to $0.73. The market value of their outstanding shares is at $5.1 million. </li>
<li>Phoenix Asia Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHOE#NASDAQ">PHOE</a>) shares increased by 19.53% to $5.63. The market value of their outstanding shares is at $121.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Robin Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBNE#NASDAQ">RBNE</a>) shares declined by 55.1% to $6.29 during Monday's regular session. The company's market cap stands at $15.0 million. </li>
<li>Dragonfly Energy Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) stock declined by 34.29% to $0.2. The market value of their outstanding shares is at $1.8 million. </li>
<li>Energys Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENGS#NASDAQ">ENGS</a>) shares decreased by 23.66% to $1.84. The company's market cap stands at $26.2 million. </li>
<li>Icon Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICON#NASDAQ">ICON</a>) shares declined by 23.08% to $2.25. The company's market cap stands at $4.9 million. </li>
<li>Hyperscale Data (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#AMEX">GPUS</a>) stock decreased by 21.15% to $3.54. The company's market cap stands at $9.9 million. </li>
<li>WANG &amp; LEE Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) shares decreased by 19.74% to $0.05. The company's market cap stands at $1.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Advanced Environmental Recycling Technologies

AERT

CREG

DFLI

ENGS

GPUS

ICON

PHOE

PPIH

RBNE

SGBX

WLGS

12 Industrials Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Sonim Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>) stock rose 61.9% to $1.5 during Monday's regular session. The market value of their outstanding shares is at $15.5 million. </li>
<li>Creative Global Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTL#NASDAQ">CGTL</a>) shares increased by 39.65% to $1.76. The market value of their outstanding shares is at $37.7 million. </li>
<li>Trident Digital Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDTH#NASDAQ">TDTH</a>) shares rose 27.21% to $0.27. The market value of their outstanding shares is at $17.3 million. </li>
<li>Global Engine Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLE#NASDAQ">GLE</a>) shares moved upwards by 23.3% to $1.64. The market value of their outstanding shares is at $30.0 million. </li>
<li>Quantum Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) stock increased by 19.66% to $19.96. The market value of their outstanding shares is at $2.8 billion. </li>
<li>Unusual Machines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UMAC#AMEX">UMAC</a>) stock rose 19.41% to $10.09. The market value of their outstanding shares is at $252.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>MicroAlgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) stock decreased by 28.6% to $0.61 during Monday's regular session. The company's market cap stands at $6.1 million. </li>
<li>XTI Aerospace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTIA#NASDAQ">XTIA</a>) shares decreased by 27.71% to $2.94. The market value of their outstanding shares is at $18.4 million. </li>
<li>Nano Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) shares fell 18.18% to $8.5. The company's market cap stands at $141.8 million. </li>
<li>FiEE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MINM#NASDAQ">MINM</a>) stock declined by 12.46% to $2.32. The company's market cap stands at $17.0 million. </li>
<li>VirnetX Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VHC#NYSE">VHC</a>) stock declined by 10.96% to $7.64. The market value of their outstanding shares is at $32.3 million. </li>
<li>Brand Engagement Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) stock decreased by 9.85% to $0.34. The market value of their outstanding shares is at $14.0 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BNAI

CGTL

MINM

MLGO

QUBT

SONM

TDTH

UMAC

XTIA

12 Information Technology Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Dawson Geophysical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWSN#NASDAQ">DWSN</a>) stock rose 130.7% to $3.16 during Monday's regular session. The market value of their outstanding shares is at $97.9 million. </li>
<li>TMD Energy Limited Ordinary Shares (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TMDE#AMEX">TMDE</a>) shares rose 83.97% to $2.41. </li>
<li>Battalion Oil (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BATL#AMEX">BATL</a>) shares increased by 60.97% to $2.64. The market value of their outstanding shares is at $43.4 million. </li>
<li>Stak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAK#NASDAQ">STAK</a>) stock increased by 51.79% to $2.96. The company's market cap stands at $33.7 million. </li>
<li>Leishen Energy Holding Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSE#NASDAQ">LSE</a>) shares increased by 51.63% to $7.73. The market value of their outstanding shares is at $131.6 million. </li>
<li>Marine Petroleum Tr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARPS#NASDAQ">MARPS</a>) shares increased by 21.05% to $5.49. The market value of their outstanding shares is at $10.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TOP Ships (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOPS#AMEX">TOPS</a>) stock decreased by 31.1% to $6.63 during Monday's regular session. The company's market cap stands at $30.6 million. </li>
<li>Houston American Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/HUSA#AMEX">HUSA</a>) stock fell 31.06% to $10.79. The market value of their outstanding shares is at $16.9 million. </li>
<li>US Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEG#NASDAQ">USEG</a>) stock fell 18.55% to $1.8. The market value of their outstanding shares is at $61.1 million. </li>
<li>Indonesia Energy Corp (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INDO#AMEX">INDO</a>) stock decreased by 16.8% to $4.31. The market value of their outstanding shares is at $58.6 million. </li>
<li>Crown LNG Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBS#NASDAQ">CGBS</a>) stock fell 11.03% to $0.1. The market value of their outstanding shares is at $46.1 million. </li>
<li>KLX Energy Services Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLXE#NASDAQ">KLXE</a>) stock decreased by 11.0% to $2.51. The company's market cap stands at $44.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-energy-stocks/" title="www.benzinga.com/money/best-energy-stocks/">www.benzinga.com/money/best-energy-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BATL

CGBS

DWSN

HUSA

INDO

KLXE

MARPS

STAK

TMDE

TOPS

USEG

12 Energy Stocks Moving In Monday's Intraday Session

Bank of America Securities (BofA) analyst Vivek Arya has reinstated its coverage of Allegro Microsystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) with a Buy rating and a price forecast of $38 per share.
Arya highlighted that Allegro is the leader in producing magnetic sensors critical to the operation of electric vehicles (EVs) and safety-focused advanced driver assist systems (ADAS).
The analyst also mentioned that the company is poised to gain from emerging opportunities in power management chips for data centers and clean energy.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45909439/nvidia-stock-could-get-boost-from-1-5-trillion-european-ai-build-out-analyst-says-significant-upside-in-shares" rel="noreferrer noopener">Nvidia Stock Could Get Boost From $1.5 Trillion European AI Build-Out: Analyst Says &#8216;Significant Upside In Shares&#8217;</a>
Despite short-term weakness in auto demand, the analyst asserted that Allegro is poised for a cyclical recovery, potentially driving an industry-leading 13% sales and 46% adjusted EPS compounded annual growth rate (CAGR) from calendar 2024 to 2027. These growth projections represent 1.3 times the sales growth and 3 times the earnings growth compared to Allegro&#8217;s industry peers.
Arya highlighted a significant growth opportunity for Allegro, projecting the company will compete in a $12 billion serviceable available market (SAM) by 2030. This market, encompassing magnetic sensors (65% of Allegro&#8217;s sales) and power ICs (35%), is expected to expand at a 9% CAGR from 2024 to 2030.
Inside this market, Auto is an $8 billion SAM growing at a 7% CAGR, while Industrial is $4 billion and tracking at a 12% CAGR across multiple high-growth submarkets, the analyst pointed out. As per him, ALGM should outgrow both markets in the long run.
Arya said auto semiconductors emerge from a deep cyclical correction, where orders pulled back ~35% from the peak. The recovery could be lumpy, but the analyst noted that Allegro could benefit from a faster mix shift to autos with content-rich e-mobility features.
Arya forecasted $1.1 billion calendar 2027 sales (in line with calendar 2023 peak) at 27% EBIT margin (below 30% peak) and $1.35 in adjusted EPS (below $1.47 peak).
Arya projects a potential upside scenario where adjusted EPS could reach $2 by 2027, significantly above consensus, provided the company accelerates sales growth to 20% versus 13% from share gains, restores gross margins to 58% (currently ~46%), and achieves its 32% EBIT margin target (currently ~9%) through disciplined spending.
Arya expressed caution about the automotive semiconductor market, predicting its recovery will be slower than that of the industrial sector. He cited key headwinds: intense competition from both larger (Infineon) and smaller (Melexis) rivals, along with risks to premium auto demand from potential tariffs and changing consumer preferences.
Arya pointed to a potential stock overhang from Sanken Electric, which holds a 32% stake in the company and will be free to sell shares when its lock-up period expires in September.
A key risk, he concluded, is that Allegro&#8217;s premium valuation (35 times calendar 2026 PE) could be compressed by greater market volatility. Arya projected fiscal 2026 revenue of $831 million and adjusted EPS of $0.51.
Price Action: ALGM stock is trading higher by 8.31% to $31.03 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45949332/broadcom-marvell-ride-the-30b-asic-wave-but-only-one-looks-ready-for-takeoff" target="_blank" rel="noreferrer noopener">Broadcom, Marvell Ride The $30B ASIC Wave – But Only One Looks Ready For Takeoff</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Initiation

Trading Ideas

ALGM

Allegro MicroSystems Being The Leader In Critical Magnetic Sensors For EVs Justifies Premium Valuation: Analyst

WIIM

Sutro Biopharma shares are trading higher after the company announced it secured a $1.06 million three-year deal to deliver External Certification Authority Token Certificate credentials to a U.S.-based aerospace and defense contractor

<figure class="wp-block-image size-large"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2025/06/2025-06-16_08h51_43-done.png" alt="" /></figure>
To gain an edge, this is what you need to know today.
<h4 class="wp-block-heading">Aggressive Stock Buying</h4>
Please <a href="https://thearorareport.com/stock-market-chart-analysis-iran-israel-war-oil-cl_f-mc-06162025">click here</a> for an enlarged chart of oil futures (CL_F).
Note the following:
<ul class="wp-block-list">
<li>The chart shows this morning oil has been progressively dropping.</li>
<li>The VUD indicator is the most sensitive measure of net supply demand in real-time. The orange represents net supply and the green represents net demand.&nbsp; The chart shows the VUD indicator is mostly orange, indicating net supply of oil.</li>
<li>Going into the weekend, the positioning was one sided in favor of oil going up.&nbsp; To understand one sided positioning, think of a boat where everyone is on one side.&nbsp; As long as the waters are calm, the boat continues to float, but when a storm hits, the boat can capsize.&nbsp; Positioning is an important Wall Street mechanic.&nbsp; Understanding positioning can give you an edge.</li>
<li>This morning, several factors are working against the price of oil. 
<ul class="wp-block-list">
<li>Positioning was one sided coming into this morning.</li>
<li>Israel has not attacked Iran's oil export facilities.&nbsp; Israel is attacking oil facilities that cater to Iran's domestic consumption.</li>
<li>Iran has indicated that it does not want to block the Strait of Hormuz.&nbsp; The Strait of Hormuz is a narrow passageway through which about 25% of the world's oil is transported.</li>
<li>The U.S. has built up a massive naval presence in the area.</li>
<li>President Trump has indicated that the U.S. may intervene.</li>
</ul>
</li>
<li>There is aggressive buying in stocks for the following reasons: 
<ul class="wp-block-list">
<li>Oil is dropping.</li>
<li>A statement from President Trump that he is open to intervention.</li>
<li>Israel has gained total control of the skies over Iran's capital Tehran.</li>
<li>Israel's prime minister Netanyahu is saying "we are on a path to victory."</li>
</ul>
</li>
</ul>
<h4 class="wp-block-heading">Magnificent Seven Money Flows</h4>
In the early trade, money flows are positive in Apple Inc (AAPL), Amazon.com, Inc. (AMZN), Alphabet Inc Class C (GOOG), Meta Platforms Inc (META), Microsoft Corp (MSFT), NVIDIA Corp (NVDA), and Tesla Inc (TSLA).
In the early trade, money flows are positive in SPDR S&amp;P 500 ETF Trust (SPY) and Invesco QQQ Trust Series 1 (QQQ).
<h4 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h4>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust (GLD).  The most popular ETF for silver is iShares Silver Trust (SLV).  The most popular ETF for oil is United States Oil ETF (USO).
<h4 class="wp-block-heading">Bitcoin</h4>
Bitcoin is range bound.
<h4 class="wp-block-heading">Arora Protection Band And What To Do Now</h4>
It is important for investors to look ahead and not in the rearview mirror.  Our proprietary Protection Band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h4 class="wp-block-heading">Traditional 60/40 Portfolio</h4>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Equities

Government

Long Ideas

Market Summary

Commodities

Opinion

Markets

Aggressive Stock Buying On Oil Drop And Israel Gaining Control Of Tehran Skies

JPMorgan hosted Abercrombie &amp; Fitch (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANF#NYSE">ANF</a>) CEO Fran Horowitz, COO Scott Lipesky, CFO Robert Ball, and VP of Investor Relations Mo Gupta <a href="https://www.benzinga.com/quote/ANF/news">for investor meetings.</a>
Analyst Matthew Boss says that CEO Horowitz sees ANF "beginning the next chapter of diversified &amp; agnostic revenue growth" focused on driving the lifetime value of customers.
In May, the retailer reported first-quarter adjusted EPS of&nbsp;$1.59, beating&nbsp;the street estimate of&nbsp;$1.40, and sales of&nbsp;$1.1 billion&nbsp;outpaced the analyst&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45677573/abercrombies-sales-strength-hollister-momentum-offset-tariff-pressure-analyst-says" rel="noreferrer noopener">consensus estimate of&nbsp;$1.08 billion</a>.
Abercrombie &amp; Fitch revised FY25 guidance for net sales growth to 3%&nbsp;to&nbsp;6%&nbsp;(from 3%&nbsp;to&nbsp;5% prior) and EPS to $9.50 to $10.50 (from $10.40&nbsp;to $11.40)&nbsp;vs. street view of $10.75.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45663155/af-absorbs-tariff-impact-no-hikes-despite-50-million-cost-plans-to-open-100-new-physical-experiences-in-2025" rel="noreferrer noopener">Abercrombie &amp; Fitch Absorbs Tariff Impact, No Price Hike Despite $50 Million Cost: Plans To Open 100 New &#8216;Physical Experiences&#8217; In 2025</a>
Despite mitigation efforts, the full-year outlook includes an estimated $50 million (100 basis points&nbsp;of net sales) in tariff expenses.
Boss writes that following marketing and merchandising improvements over the last few years, the Abercrombie brand has successfully expanded its customer reach to an 18 to 40-year-old demographic.
Substantial new customer acquisition globally supports broad-based top-line results and greater full-price selling.
The analyst also sees international brand growth picking up, with about $400 million in revenue still to be regained compared to pre-pandemic levels. Over the long term, Boss expects steady annual growth in profit margins, helped by lower occupancy costs and a stronger overall profit margin than before the pandemic.
The management noted traffic and new customer growth to the Abercrombie brand, which stands "nicely" positive year over year, with customers responding well to the Vacation Shop.
The analyst on Monday <a href="https://www.benzinga.com/quote/ANF/analyst-ratings" target="_blank" rel="noreferrer noopener">maintained an Overweight rating</a> and a price target of $141, down from $147, based on around 7x the estimated fiscal 2026 EBITDA.
Management said that about 50% of their inventory budget for the second half of 2025 is still available. They plan to keep things flexible to respond quickly to strong-performing product categories during the Fall season.
Boss said the company's management sees strong international growth potential across both brands. Currently, international sales make up about 19% of total sales, compared to around 35% in the past.
Management highlighted solid performance in early expansion markets like Germany and the UK and sees more room to grow. Most current international sales come from the Hollister brand, suggesting a significant opportunity for the Abercrombie brand to expand and gain market share overseas.
Price Action: ANF stock is up 0.5% at $75.06 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45891695/bofa-securities-warns-tariffs-could-still-weigh-on-retail-stocks-such-as-gap-ralph-lauren" target="_blank" rel="noreferrer noopener">BofA Securities Warns Tariffs Could Still Weigh On Retail Stocks Such As Gap, Ralph Lauren</a></li>
</ul>
Photo: Shutterstock

Retail Sales

General

Abercrombie Shifts Strategy: Can It Win Over A New Generation Worldwide?

AMAT

CNBC Halftime Report Final Trades: Applied Materials, Walt Disney Company, Vistra Corp

Landbase, a San Francisco-based AI company aiming to revolutionize how small and midsize businesses launch outbound <a href="https://www.benzinga.com/news/25/04/45027754/glade-brook-leads-25m-bet-on-artisan-the-ai-startup-backed-by-y-combinator-hubspot-and-sequoia-to-replace-human-sales-teams">sales</a>,<a href="https://www.landbase.com/blog/landbase-raises-30-million-series-a-to-help-businesses-find-their-next-customer"> announced</a> Thursday a $30 million Series A round co-led by actor Ashton Kutcher's Sound Ventures and Picus Capital. The round also included continued participation from existing investors including 8VC, A&#x2A;, and Firstminute Capital.
Founded by Daniel Saks, previously co-CEO of AppDirect, Landbase uses its proprietary AI model GTM-1 Omni to help business-to-business companies automate hyper-personalized outreach campaigns across channels. According to<a href="https://techcrunch.com/2025/06/12/how-ai-sales-startup-landbase-nabbed-ashton-kutchers-sound-ventures-to-lead-its-30m-series-a/"> TechCrunch</a>, the platform, built on <a href="https://www.benzinga.com/news/topics/25/06/45790909/was-jeff-bezos-backed-whylabs-secretly-acquired-by-apple-after-10m-series-a-to-compete-in-ai-arms-race-against-google-openai-and-microsoft">OpenAI</a>'s GPT-4o and trained on 40 million real-world marketing campaigns, delivers predictive intelligence with reinforcement learning and human oversight.
Don't Miss:
<ul class="wp-block-list">
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – Many are rushing to <a href="https://www.benzinga.com/money/mode-mobile-2">grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
<h2 class="wp-block-heading">Landbase's GTM-1 Omni Targets Trust Deficit in Outbound Marketing</h2>
Landbase's core thesis emerged from Saks' own experience, including a surprising cold outreach from Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) CEO Michael Dell via LinkedIn while Saks was at AppDirect, TechCrunch says.
&#8220;I thought it was fake," Saks told TechCrunch. "So I'm getting ready for this call, thinking there's no way it's Michael Dell. And I'm almost kind of laughing about it. It actually was Michael." That encounter highlighted the power of recognition in digital outreach and led to the concept of "digital trust," now central to Landbase's model.
Rather than attempting to replace human sales reps, Landbase's platform uses what Saks calls "vibe GTM," applying AI to automate outreach while keeping humans in control of messaging. <a href="https://www.landbase.com/blog/landbase-raises-30-million-series-a-to-help-businesses-find-their-next-customer">The company says</a> campaigns built with GTM-1 Omni have delivered 4x to 7x higher conversion rates compared to traditional methods, and reduced average launch time from 14 days to just minutes.
Trending: Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.
<h2 class="wp-block-heading">Celebrity-Backed, Investor-Supported, and Growing Rapidly</h2>
Sound Ventures, which also backs OpenAI, Anthropic, Stability AI, and Hugging Face, saw Landbase as a natural extension of its AI investment thesis. During the pitch, Kutcher proposed replacing the company's original tagline, &#8220;intelligently automate your go-to-market&#8221; with &#8220;find your next customer,&#8221; which Saks told TechCrunch helped seal the deal.
Since launching in late 2024, Landbase has grown from 10 paid customers to over 100, fueled largely by campaigns run on its own platform. The Series A raise attracted 130 inbound inquiries from venture firms, and Saks met with 50 top-tier funds during a multi-city roadshow, TechCrunch says.
"Because we were focusing on our digital trust, we started to get a slew of inbound from investors," Saks told TechCrunch.
See Also: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>
<h2 class="wp-block-heading">Landbase Makes AI Outreach Accessible to Small Business</h2>
Landbase's platform is now available in a freemium model, offering campaign planning tools at no cost and multichannel execution starting at $3,000 per month. Unlike competitors that focus on tech startups, TechCrunch says that Landbase is targeting industries like insurance, commercial landscaping, and managed service providers.
Saks told TechCrunch that the company is focused on expanding GTM-1 Omni's capabilities, deepening partnerships with marketing data providers, and improving campaign quality for under-resourced teams. Future updates will include broader industry coverage and additional pricing tiers designed to support a wide range of small and medium businesses.
Landbase joins a crowded field that includes Regie.ai, AiSDR, ZoomInfo, HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>), Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>), and Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), but aims to stand out by prioritizing control, transparency, and trust over AI gimmickry, TechCrunch reports. With strong early metrics and endorsement from high-profile backers, the company may be a next-generation solution for digital growth.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/how-peter-thiel-turned-his-roth-ira-into-5-billion-and-why-accredited-investors-are-now-eyeing-this-smartphone-disruptor">with $1,000 you can invest at just $0.30/share!</a></li>
</ul>
Image: Shutterstock

DELL

HUBS

MSFT

Ashton Kutcher's Sound Ventures And Picus Capital Dropped $30M On Daniel Saks' Landbase To Revolutionize AI‑Driven 'Vibe GTM' Outreach

Eli Lilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) short percent of float has risen 9.78% since its last report. The company recently reported that it has 8.03 million shares sold short, which is 1.01% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.05 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Eli Lilly Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750093282_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Eli Lilly has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Eli Lilly's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Eli Lilly's peer group average for short interest as a percentage of float is 4.03%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is the Market Bullish or Bearish on Eli Lilly?

Republic Services's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>) short percent of float has risen 23.53% since its last report. The company recently reported that it has 2.97 million shares sold short, which is 1.47% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.08 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Republic Services Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750093277_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Republic Services has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Republic Services's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Republic Services's peer group average for short interest as a percentage of float is 3.02%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Is Republic Services Gaining or Losing Market Support?

Travelers Companies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) short percent of float has risen 3.52% since its last report. The company recently reported that it has 3.33 million shares sold short, which is 1.47% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.84 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Travelers Companies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750093272_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Travelers Companies has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Travelers Companies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Travelers Companies's peer group average for short interest as a percentage of float is 2.57%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

What Does the Market Think About Travelers Companies?

Whales with a lot of money to spend have taken a noticeably bullish stance on Sarepta Therapeutics.
Looking at options history for Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) we detected 38 trades.
If we consider the specifics of each trade, it is accurate to state that 50% of the investors opened trades with bullish expectations and 36% with bearish.
From the overall spotted trades, 26 are puts, for a total amount of $2,831,990 and 12, calls, for a total amount of $551,179.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $70.0 for Sarepta Therapeutics over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Sarepta Therapeutics's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Sarepta Therapeutics's significant trades, within a strike price range of $20.0 to $70.0, over the past month.
<h3>Sarepta Therapeutics 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750093249_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$25.7</td>
<td>$25.5</td>
<td>$25.7</td>
<td>$45.00</td>
<td>$514.0K</td>
<td>9.5K</td>
<td align="right">302</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$51.3</td>
<td>$49.0</td>
<td>$49.0</td>
<td>$70.00</td>
<td>$490.0K</td>
<td>311</td>
<td align="right">100</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$14.1</td>
<td>$14.0</td>
<td>$14.0</td>
<td>$35.00</td>
<td>$350.0K</td>
<td>2.3K</td>
<td align="right">257</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$27.2</td>
<td>$25.5</td>
<td>$25.7</td>
<td>$45.00</td>
<td>$257.0K</td>
<td>9.5K</td>
<td align="right">102</td>
</tr>
<tr>
<td>SRPT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/27/25</td>
<td>$17.3</td>
<td>$16.4</td>
<td>$16.7</td>
<td>$35.00</td>
<td>$167.0K</td>
<td>806</td>
<td align="right">212</td>
</tr>
</tbody>
</table>

<h3>About Sarepta Therapeutics</h3>
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.
After a thorough review of the options trading surrounding Sarepta Therapeutics, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Sarepta Therapeutics's Current Market Status</h3>
<ul>
<li>Trading volume stands at 29,232,577, with SRPT's price down by -41.29%, positioned at $21.24.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 51 days.</li>
</ul>
<h3>What Analysts Are Saying About Sarepta Therapeutics</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $52.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Needham persists with their Buy rating on Sarepta Therapeutics, maintaining a target price of $50. 
&#x2A; In a positive move, an analyst from Scotiabank has upgraded their rating to Sector Outperform and adjusted the price target to $80. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Sarepta Therapeutics, targeting a price of $84. 
&#x2A; An analyst from HC Wainwright &amp; Co. has revised its rating downward to Sell, adjusting the price target to $10. 
&#x2A; In a cautious move, an analyst from Piper Sandler downgraded its rating to Neutral, setting a price target of $36. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Sarepta Therapeutics, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

What the Options Market Tells Us About Sarepta Therapeutics

Whales with a lot of money to spend have taken a noticeably bearish stance on Wells Fargo.
Looking at options history for Wells Fargo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) we detected 20 trades.
If we consider the specifics of each trade, it is accurate to state that 45% of the investors opened trades with bullish expectations and 55% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $232,550 and 15, calls, for a total amount of $2,561,239.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $40.0 to $82.5 for Wells Fargo over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Wells Fargo's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Wells Fargo's substantial trades, within a strike price spectrum from $40.0 to $82.5 over the preceding 30 days.
<h3>Wells Fargo 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750093244_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WFC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$0.31</td>
<td>$0.29</td>
<td>$0.31</td>
<td>$82.50</td>
<td>$847.5K</td>
<td>32.3K</td>
<td>30.0K</td>
</tr>
<tr>
<td>WFC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.05</td>
<td>$4.95</td>
<td>$4.98</td>
<td>$77.50</td>
<td>$498.0K</td>
<td>7.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>WFC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$34.65</td>
<td>$34.1</td>
<td>$34.11</td>
<td>$40.00</td>
<td>$341.0K</td>
<td>1.8K</td>
<td>100</td>
</tr>
<tr>
<td>WFC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$12.45</td>
<td>$12.3</td>
<td>$12.45</td>
<td>$65.00</td>
<td>$158.1K</td>
<td>11.7K</td>
<td>370</td>
</tr>
<tr>
<td>WFC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$12.45</td>
<td>$12.35</td>
<td>$12.45</td>
<td>$65.00</td>
<td>$153.6K</td>
<td>11.7K</td>
<td>243</td>
</tr>
</tbody>
</table>

<h3>About Wells Fargo</h3>
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company has four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the US
Following our analysis of the options activities associated with Wells Fargo, we pivot to a closer look at the company's own performance.
<h3>Where Is Wells Fargo Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 4,532,408, with WFC's price up by 1.51%, positioned at $73.45.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 28 days.</li>
</ul>
<h3>What The Experts Say On Wells Fargo</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $87.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Buy rating for Wells Fargo, targeting a price of $90. 
&#x2A; An analyst from Goldman Sachs persists with their Buy rating on Wells Fargo, maintaining a target price of $86. 
&#x2A; Consistent in their evaluation, an analyst from Evercore ISI Group keeps a Outperform rating on Wells Fargo with a target price of $88. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Wells Fargo, maintaining a target price of $87. 
&#x2A; An analyst from Piper Sandler has revised its rating downward to Overweight, adjusting the price target to $85. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Wells Fargo options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Wells Fargo Unusual Options Activity For June 16

Press Releases

Quince Therapeutics to Host Investor Webinar on February 7, 2025 Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia

Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia

Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results

Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference

Quince Therapeutics to Present at Citizens Life Sciences Conference

Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia

Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities

Comments

Quince Therapeutics

Noticias

Últimas noticias sobre Quince Therapeutics (NASDAQ:QNCX) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL